Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers

International Journal of Gynecological Pathology

Volumn 35, Issue 5, 2016, Pages 410-418

  Ramalingam, Preetha ^a   Masand, Ramya P ^a   Euscher, Elizabeth D ^a   Malpica, Anais ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Basal like carcinoma; Carcinoma; Endometrium; Hormone receptors; Immunohistochemistry; Microsatellite instability; PAX 8; Undifferentiated carcinoma

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 8; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; NEU 33 PROTEIN; PROGESTERONE RECEPTOR; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P16; PROTEIN P53; STEM CELL FACTOR; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN RECEPTOR; ANTIBODY; PAX8 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BASAL LIKE CARCINOMA; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNDIFFERENTIATED CARCINOMA; WILD TYPE; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; METABOLISM; MISMATCH REPAIR; OVARIAN NEOPLASMS; PATHOLOGY;

ANTIBODIES; BIOMARKERS, TUMOR; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PAX8 TRANSCRIPTION FACTOR;

EID: 84947967817     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000248     Document Type: Article

References (19)

1. Altrabulsi B, Malpica A, Deavers MT, et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005; 29:1316-21
2. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006;106:87-94
3. Saad RS, Mashhour M, Noftech-Mozes S, et al. P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin. Int J Gynecol Pathol. 2012;31:57-65
4. Tafe LJ, Garg K, Chew I, et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781-9
5. Silva EG, Tornos C, Bailey MA, et al. Undifferentiated carcinoma of the ovary. Arch Pathol Lab Med. 1991;115:377-81
6. Ozcan A, Liles N, Coffey D, et al. PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35:1837-47
7. Holmes BJ, Gown AM, Vang R, et al. PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma). Int J Gynecol Pathol. 2014;33:425-31
8. Laury AR, Hornick JL, Perets R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627-35
9. Laury AR, Perets R, Piao H, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816-26
10. Yemelyanova A, Gown AM, Wu LS, et al. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations. Int J Gynecol Pathol. 2014;33:492-9
11. Bishop JA, Sharma R, Westra WH. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol. 2011;42:1873-7
12. Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol. 2008;21:192-200
13. Alkushi A, Kobel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 2010;29:343-50
14. Chiesa-Vottero AG, Malpica A, Deavers MT, et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol. 2007;26:328-33
15. Djordjevic B, Barkoh BA, Luthra R, et al. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas. Mod Pathol. 2013;26:1401-12
16. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19:264-71
17. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14: 1368-76
18. Nalwoga H, Arnes JB, Wabinga H, et al. Expression of EGFR and c-kit is associated with the basal-like phenotype in breast carcinomas of African women. APMIS. 2008;116:515-25
19. Romero-Pérez L, Lopez-Garcia MA, Diaz-Martin J, et al. ZEB1 overexpression associated with E-cadherin and micro- RNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 2013;26:1514-24